SPRB Spruce Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SPRB

Price (delayed)

$0.7444

Market cap

$30.63M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.24

Enterprise value

-$61.35M

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet need. Spruce is initially developing its wholly-owned product candidate, ...

Highlights
Spruce Biosciences's gross profit has increased by 40% QoQ
The revenue has grown by 40% from the previous quarter
SPRB's equity is up by 12% year-on-year but it is down by 10% since the previous quarter
SPRB's net income is down by 3.8% year-on-year but it is up by 2.4% since the previous quarter
SPRB's quick ratio is down by 38% year-on-year and by 12% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.sprucebiosciences.com
Peers: OMER OMGA

Key stats

What are the main financial stats of SPRB
Market
Shares outstanding
41.15M
Market cap
$30.63M
Enterprise value
-$61.35M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.4
Price to sales (P/S)
2.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-6.08
Earnings
Revenue
$10.09M
EBIT
-$47.44M
EBITDA
-$47.14M
Free cash flow
-$33.28M
Per share
EPS
-$1.24
Free cash flow per share
-$0.86
Book value per share
$1.88
Revenue per share
$0.26
TBVPS
$2.7
Balance sheet
Total assets
$103.95M
Total liabilities
$27.44M
Debt
$4.36M
Equity
$76.51M
Working capital
$77.72M
Liquidity
Debt to equity
0.06
Current ratio
4.18
Quick ratio
3.94
Net debt/EBITDA
1.95
Margins
EBITDA margin
-467.2%
Gross margin
100%
Net margin
-475%
Operating margin
-515.3%
Efficiency
Return on assets
-39.8%
Return on equity
-52.3%
Return on invested capital
-459.9%
Return on capital employed
-59.7%
Return on sales
-470.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SPRB stock price

How has the Spruce Biosciences stock price performed over time
Intraday
0.59%
1 week
6.34%
1 month
-9.63%
1 year
-66.01%
YTD
-74.59%
QTD
-5.28%

Financial performance

How have Spruce Biosciences's revenue and profit performed over time
Revenue
$10.09M
Gross profit
$10.09M
Operating income
-$51.99M
Net income
-$47.92M
Gross margin
100%
Net margin
-475%
Spruce Biosciences's gross profit has increased by 40% QoQ
The revenue has grown by 40% from the previous quarter
The company's operating margin rose by 30% QoQ
Spruce Biosciences's net margin has increased by 30% QoQ

Growth

What is Spruce Biosciences's growth rate over time

Valuation

What is Spruce Biosciences stock price valuation
P/E
N/A
P/B
0.4
P/S
2.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-6.08
SPRB's EPS is up by 37% year-on-year and by 17% since the previous quarter
The stock's price to book (P/B) is 64% less than its last 4 quarters average of 1.1
SPRB's equity is up by 12% year-on-year but it is down by 10% since the previous quarter
The P/S is 86% less than the last 4 quarters average of 20.2
The revenue has grown by 40% from the previous quarter

Efficiency

How efficient is Spruce Biosciences business performance
SPRB's return on invested capital has dropped by 157% since the previous quarter
SPRB's return on sales is up by 30% since the previous quarter
SPRB's return on assets is up by 14% year-on-year and by 6% since the previous quarter
The return on equity has increased by 4.7% year-on-year and by 4.6% since the previous quarter

Dividends

What is SPRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SPRB.

Financial health

How did Spruce Biosciences financials performed over time
The company's total liabilities has surged by 60% YoY
SPRB's current ratio is down by 38% year-on-year and by 9% since the previous quarter
Spruce Biosciences's debt is 94% lower than its equity
SPRB's debt to equity is down by 33% YoY
Spruce Biosciences's debt has decreased by 29% YoY and by 10% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.